Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria

Hiroki Kawano, Kentaro Minagawa, Kanako Wakahashi, Yuko Kawano, Akiko Sada, Toshimitsu Matsui, Hirotaka Hirano, Hideyuki Shiomi, Yonson Ku, Yoshio Katayama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) makes patients susceptible to intravascular hemolysis and thrombosis, and it can be life-threatening in stressful situations. Eculizumab, a humanized monoclonal antibody that inhibits the complement protein C5, has been evaluated as a novel therapy for PNH. We herein describe the case of a 59-year-old Japanese woman with classic PNH, who had been successfully treated with eculizumab, but who later developed acute cholecystitis/cholangitis from gallstones. Although the severe obstructive jaundice requiring endoscopic therapy following cholecystectomy was complicated, critical intravascular hemolysis and thrombosis were not observed. Therefore, utilizing eculizumab during the peri-operative management of PNH patients should be carefully taken into consideration.

Original languageEnglish (US)
Pages (from-to)2613-2616
Number of pages4
JournalInternal Medicine
Volume51
Issue number18
DOIs
StatePublished - Oct 30 2012

Fingerprint

Paroxysmal Hemoglobinuria
Obstructive Jaundice
Gallstones
Hemolysis
Thrombosis
Complement C5
Antibodies, Monoclonal, Humanized
Acute Cholecystitis
Cholangitis
Cholecystectomy
Complement System Proteins
eculizumab
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Kawano, Hiroki ; Minagawa, Kentaro ; Wakahashi, Kanako ; Kawano, Yuko ; Sada, Akiko ; Matsui, Toshimitsu ; Hirano, Hirotaka ; Shiomi, Hideyuki ; Ku, Yonson ; Katayama, Yoshio. / Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria. In: Internal Medicine. 2012 ; Vol. 51, No. 18. pp. 2613-2616.
@article{863e9d06a401411ba258b028dcea3556,
title = "Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria",
abstract = "Paroxysmal nocturnal hemoglobinuria (PNH) makes patients susceptible to intravascular hemolysis and thrombosis, and it can be life-threatening in stressful situations. Eculizumab, a humanized monoclonal antibody that inhibits the complement protein C5, has been evaluated as a novel therapy for PNH. We herein describe the case of a 59-year-old Japanese woman with classic PNH, who had been successfully treated with eculizumab, but who later developed acute cholecystitis/cholangitis from gallstones. Although the severe obstructive jaundice requiring endoscopic therapy following cholecystectomy was complicated, critical intravascular hemolysis and thrombosis were not observed. Therefore, utilizing eculizumab during the peri-operative management of PNH patients should be carefully taken into consideration.",
author = "Hiroki Kawano and Kentaro Minagawa and Kanako Wakahashi and Yuko Kawano and Akiko Sada and Toshimitsu Matsui and Hirotaka Hirano and Hideyuki Shiomi and Yonson Ku and Yoshio Katayama",
year = "2012",
month = "10",
day = "30",
doi = "10.2169/internalmedicine.51.8202",
language = "English (US)",
volume = "51",
pages = "2613--2616",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "18",

}

Kawano, H, Minagawa, K, Wakahashi, K, Kawano, Y, Sada, A, Matsui, T, Hirano, H, Shiomi, H, Ku, Y & Katayama, Y 2012, 'Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria', Internal Medicine, vol. 51, no. 18, pp. 2613-2616. https://doi.org/10.2169/internalmedicine.51.8202

Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria. / Kawano, Hiroki; Minagawa, Kentaro; Wakahashi, Kanako; Kawano, Yuko; Sada, Akiko; Matsui, Toshimitsu; Hirano, Hirotaka; Shiomi, Hideyuki; Ku, Yonson; Katayama, Yoshio.

In: Internal Medicine, Vol. 51, No. 18, 30.10.2012, p. 2613-2616.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria

AU - Kawano, Hiroki

AU - Minagawa, Kentaro

AU - Wakahashi, Kanako

AU - Kawano, Yuko

AU - Sada, Akiko

AU - Matsui, Toshimitsu

AU - Hirano, Hirotaka

AU - Shiomi, Hideyuki

AU - Ku, Yonson

AU - Katayama, Yoshio

PY - 2012/10/30

Y1 - 2012/10/30

N2 - Paroxysmal nocturnal hemoglobinuria (PNH) makes patients susceptible to intravascular hemolysis and thrombosis, and it can be life-threatening in stressful situations. Eculizumab, a humanized monoclonal antibody that inhibits the complement protein C5, has been evaluated as a novel therapy for PNH. We herein describe the case of a 59-year-old Japanese woman with classic PNH, who had been successfully treated with eculizumab, but who later developed acute cholecystitis/cholangitis from gallstones. Although the severe obstructive jaundice requiring endoscopic therapy following cholecystectomy was complicated, critical intravascular hemolysis and thrombosis were not observed. Therefore, utilizing eculizumab during the peri-operative management of PNH patients should be carefully taken into consideration.

AB - Paroxysmal nocturnal hemoglobinuria (PNH) makes patients susceptible to intravascular hemolysis and thrombosis, and it can be life-threatening in stressful situations. Eculizumab, a humanized monoclonal antibody that inhibits the complement protein C5, has been evaluated as a novel therapy for PNH. We herein describe the case of a 59-year-old Japanese woman with classic PNH, who had been successfully treated with eculizumab, but who later developed acute cholecystitis/cholangitis from gallstones. Although the severe obstructive jaundice requiring endoscopic therapy following cholecystectomy was complicated, critical intravascular hemolysis and thrombosis were not observed. Therefore, utilizing eculizumab during the peri-operative management of PNH patients should be carefully taken into consideration.

UR - http://www.scopus.com/inward/record.url?scp=84867876767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867876767&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.51.8202

DO - 10.2169/internalmedicine.51.8202

M3 - Article

C2 - 22989836

AN - SCOPUS:84867876767

VL - 51

SP - 2613

EP - 2616

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 18

ER -